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Abstract
Introduction Chronic hepatitis B (CHB) affects over 350
million people worldwide and can lead to life-threatening
complications, including liver failure and hepatocellular
cancer (HCC). Modern antiviral therapies could stem the
rising tide of hepatitis B-related HCC, provided that
individuals and populations at risk can be reliably
identified through hepatitis B screening and appropriately
linked to care. Opportunistic disease screening cannot
deliver population-level outcomes, given the large number
of undiagnosed people, but they may be achievable through
well-organized and targeted community-based screening
interventions.
Material and methods This review summarizes the
experience with community-based CHB screening pro-
grams published in the English-language literature over the
last 30 years.
Results They include experiences from Taiwan, the
USA, The Netherlands, New Zealand, and Australia.
Despite great variability in program setting and design,
successful programs shared common features, including
effective community engagement incorporating the target
population’s cultural values and the ability to provide low-
cost or free access to care, including antiviral treatment.
Conclusion While many questions still remain about the
best funding mechanisms to ensure program sustainability
and what the most effective strategies are to ensure pro-
gram reach, linkage to care, and access to treatment, the
evidence suggests scope for cautious optimism. A number
of successful, large-scale initiatives in the USA, Asia–
Pacific, and Europe demonstrated the feasibility of com-
munity-based interventions in effectively screening large
numbers of people with CHB. By providing an effective
mechanism for community outreach, scaling up these
interventions could deliver population-level outcomes in
liver cancer prevention relevant for many countries with a
large burden of disease.
Keywords Chronic hepatitis B  Hepatocellular cancer 
Cancer screening and prevention  Community-based
screening
Background
Chronic infection with hepatitis B virus represents a global
public health challenge, given that approximately 350
million people are infected worldwide [1]. Approximately
95 % of infected adults and older children can successfully
clear the infection and become immune, but 90 % of
infected neonates and 25–50 % of children infected in
infancy become chronically infected [2]. Chronic hepati-
tis B (CHB) can remain asymptomatic for decades, but can
lead to cirrhosis or hepatitis B-related liver cancer (hepa-
tocellular cancer, or HCC) in approximately 25 % of cases,
explaining the 800,000 deaths/year attributable to the
infection and its complications [3, 4]. The Global Burden
of Disease study estimated that, of the 8.0 million lives lost
to cancer in 2010, HCC was second only to lung cancer in
terms of cancer deaths; half of these cases were hepatitis B
related [4].
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Over 80 % of liver cancers occur in East Asia and Sub-
Saharan Africa [5]; with increasing international migration,
increasingly they are also HCC disease determinants in
North America, Western Europe, and Australia, particu-
larly among immigrant populations [6–9]. US Vietnamese
males are 11 times more likely to develop HCC than non-
Hispanic Whites [10], and Australian males born in Viet-
nam are 13 times more likely to develop HCC than other
Australians [8].
Currently available antiviral therapies have the potential
to change the natural history of CHB, [11–14] given that
screening and treating high-risk populations appear cost
effective in studies from the USA [15], Canada [16], Aus-
tralia [17], and The Netherlands [18]. This is predicated upon
people being aware of their status and willing and able to
access regular monitoring and treatment [19], not readily
provided through opportunistic CHB screening. Current
estimates suggest that two-thirds of Americans [19] and
40 % of Australians living with CHB [20] are unaware they
are infected; in the European Union this figure may be as high
as 90 % [21], with people undiagnosed (many of them
migrants and underserved populations) destined to replicate
the natural history of the disease [22].
Community-based screening could provide CHB
screening in populations where limited English proficiency,
lower socioeconomic and educational levels, lack of health
insurance, and disease stigma preclude their ability to
effectively navigate the health care system [23], with
health care provider- and health system-related barriers
posing additional challenges [24]. Hepatitis B vaccination
is the mainstay of modern hepatitis B prevention. The
implementation of universal vaccination has led to dra-
matic reductions in the overall hepatitis B disease burden,
and as of July 2011, 179 countries reported inclusion of the
hepatitis B vaccine in their national immunization sched-
ules (up from 31 countries in 1992) [3]. However, vacci-
nation is of no benefit to those already infected, who need
to access medical care to mitigate disease outcomes [19].
Disease screening offers people already infected a gateway
into care, which needs to remain open until the pool of
existing infections is exhausted. While the approach to
screening may vary, identifying those infected remains a
priority in all countries which have sizable at-risk
populations.
This systematic review examines the evidence around
community-based hepatitis B screening, seeking to better
understand the common factors of success and challenges.
Methods
We used Rein’s definition of community-based hepatitis B
screening programs, as those that ‘‘systematically offer
HBsAg testing to all members of a population group based
on country of birth or participation in high-risk behaviour.’’
This definition excludes ‘‘screening conducted by state and
local public health departments, including screening per-
formed by refugee health programs’’ [25].
Whitehead views community-based interventions
(CBIs) as alternatives to ‘‘top-down’’ interventions
designed to improve the health and/or socioeconomic sta-
tus of the world’s poor [26]. Based upon who initiates,
drives, and carries out the intervention, he proposes seven
types of community-based interventions, ranging from
completely self-sufficient programs, driven and funded
exclusively by the community (type 1) to those planned
and implemented as equitable partnerships by the com-
munity in collaboration with an external change agent
(type 7). The continuum includes interventions involving
the recipient community to different degrees, from merely
program recipients to active partners in program imple-
mentation, with the ‘‘ideal’’ CBI being a true partnership
between technical experts and the communities they serve.
The former contributes conceptual strength, comprehensive
design, and rigorous implementation, while community
endorsement and support increase the likelihood of pro-
gram incorporation into its sociocultural context,
strengthening sustainability and diffusion [26].
We graded the effectiveness of community engagement
as ‘‘high’’ or ‘‘low’’ according to the programs’ self-
reported capacity to establish meaningful community
partnerships.
Programs were also categorized using the four hepati-
tis B screening models described by Rein et al. [27] as:
1. Community clinic model (CCM), with screening
integrated into routine primary care services; the
screening decision is informed by risk factor review,
with doctors providing counseling and testing referrals.
2. Community outreach model (COM), which involves
screening in community settings (i.e., health fairs and
community centers), with testing provided by phlebot-
omists and with volunteers providing logistical support
at screening events.
3. Partnership and contract model (PCM), in which
screening is contracted to general health screening
companies (such as wellness campaigns targeting
Asian employees).
4. Outreach and partnership model (OPM), which com-
bines elements of COM and PCM; screening takes
place in COM-type settings, with planning activities
coordinated by a community organization with direct
links to the target community.
We identified publications about community screening
programs by searching PubMed and EMBASE for articles
published in the English language from 1984 through
Hepatol Int (2014) 8:478–492 479
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January 2014, using the terms ‘‘hepatitis B testing,’’
‘‘hepatitis B screening,’’ combined with ‘‘community pro-
grams,’’ ‘‘migrant screening,’’ ‘‘CHB screening,’’ ‘‘high
risk,’’ ‘‘population,’’ and ‘‘population-based screening.’’
Articles were entered into an Endnote (version X4,
Thomson Reuters) database and identified abstracts
reviewed. Full articles were retrieved if deemed relevant,
with the list augmented with manual searches of reference
lists. Where more than one publication described the same
program, the paper providing the greatest level of detail
was used as a key reference, with additional data from
other publications included (and referenced) if they con-
tributed salient information (i.e., updates on program out-
comes). The overall search strategy is outlined in Fig. 1.
Programs not providing details about how screening was
conducted were excluded.
We extracted and tabulated the following information
for each program:
1. Screening model employed and extent of community
engagement
2. Program’s target population
3. Program partners
4. Study type




The search identified 237 papers; based upon the infor-
mation provided in the abstracts, 206 papers were exclu-
ded, leaving 31 papers for review. As four of these reports
described the same interventions (either different aspects or
at different points in time), the final number of discrete
programs was 27. Of these, 19 interventions were based in
the USA, 4 in the Netherlands, 2 in New Zealand, and 1
each in Taiwan and Australia (Table 1).
Two US papers reported aggregate results of US-based
community screening programs: one reported outcomes of
a nationwide audit of community-based hepatitis B
screening programs [25]; the other described four models
of community-based screening [27], which we also used
for consistency.
Screening model employed and estimated degree
of community engagement
An OPM was employed by 13 programs. Some were large
one-off initiatives (e.g., screening the entire population of
Kawerau, New Zealand [28], the adult population of Tai-
wan [29], the Asian American and Pacific Islander
migrants in Colorado, USA [30]), while others operated for
a longer duration, such as programs in California (Hep B
Free [31] and the Jade Ribbon Campaign in San Francisco
[32] and a program run by the Asian Liver Center in Los
Angeles [33]) and the BFreeNYC program in New York
[34, 35]. Medium-sized OPM programs screened
1,000–2,000 participants: the Hepatitis B Initiative in
Washington, DC [36], the Hepatitis Outreach Network
(HONE) program in New York [37], and the Three for Life
initiative in San Francisco [38]. Smaller OPM programs
(screening \1,000 people) were run in conjunction with
faith-based community organizations (i.e., Korean chur-
ches in New Jersey [39] and Montgomery County in
Maryland [40]) and through health fairs in Michigan [41].
In addition to hepatitis B screening, OPM programs
included specific outreach and educational activities,
including hepatitis talks, distribution of printed materials,
and web-based resources and effectively used ethnic media
for publicity.
Fig. 1 Diagrammatic
representation of the search
strategy and its outcomes
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COMs provided screening through one-off events at
community health fairs and/or community centers. All
were US based and targeted Asian Americans and Pacific
Islanders in Boston [42], Houston [43], Miami [44], and
Hawaii [45]. No ongoing community engagement was
documented, and they reached between 100 [45] and 1,000
people [42].
The HepBFree program in New Zealand used commu-
nity screening with outreach in rural areas and screening in
general practices (GPs) in Auckland [46, 47]; the latter was
also employed by a program in Virginia, which combined
testing at a local doctor’s surgery with testing at an annual
fair [48].
Multiple methods were employed by the Dutch initia-
tives: testing was offered in community centers, schools,
churches, and the Municipal Public Health Service in
Rotterdam and Arnhem [49, 50]; an Internet intervention
was trialled in Rotterdam [51], and screening at Egyptian
meeting places and the Public Health Service was offered
in Amsterdam [52].
In San Francisco, clinic-based screening was offered by
the Three for Life program [38] and through clinics run by
medical students. The Australian program offers primary
care-based screening by GPs in Sydney [53, 54].
Sufficient information allowed us to ascertain a high
degree of community involvement in eight programs; the
Australian B Positive program commenced as a clinical
intervention delivered by general practitioners and was
repositioned as a community–agency collaboration to
increase program visibility and participation rates [53].
Program target population
The target populations ranged from country-wide hepati-
tis B and C screening in Taiwan [29] to city-wide screen-
ing in New York (BFreeNYC [34]) and San Francisco (Hep
B Free) programs [31]. Screening targeted people of Asian
and/or Pacific Islander heritage in Boston [42] and Mary-
land [39, 40] and the HONE program in New York [37].
The HepBFree program in New Zealand targeted the local
Maori population, as well as Asian and Pacific Islander
residents [46, 47]. Korean and Vietnamese Americans were
the target population in Colorado [30], Korean and Chinese
Americans in the Baltimore–Washington area, LA County,
and San Francisco [31, 33], Chinese, Korean, and Viet-
namese Americans in Michigan [41], the Filipino com-
munity in Hawaii [45], and Chinese–Korean communities
in Philadelphia and New Jersey [39]. In Australia, the B
Positive program targets Chinese and Vietnamese residents
in Sydney [51], while Dutch programs targeted Chinese
and Turkish migrant communities of Rotterdam and Arn-
hem [49–51], and Egyptian migrants in Amsterdam [52].
Some US-based programs were promoted and supported
by faith-based organizations [36, 39, 40], and some were
offered by clinical groups offering education and testing at
community events [30, 43, 45]; while some screened all
participants (in Miami, FL and Houston, TX) [43, 44],
others based testing decision on risk factors (Colorado)
[30].
In New Zealand, testing was offered at Maori meeting
places (marae), mobile caravans, and through GP offices
[46]. In Australia, it is offered through GP offices [54], and
in The Netherlands at community sites and Municipal
Public Health Services [49–52]. The Taiwanese program
invited participants to attend clinics at designated screening
stations [29].
Program partners
Most programs were the result of collaborations between
academic institutions or clinics and community-based
organizations; some also had support from local public
health units. The number of community partners ranged
from[400 in the case of San Francisco Hep B Free [32] to
just the agency delivering the intervention [41, 44].
Study type
Two reports described controlled intervention studies: one
was a church-based HBV screening and vaccination pilot
program in Philadelphia [39], the other a randomized
controlled trial (RCT) conducted in The Netherlands [51].
The US pilot study recruited 330 Korean Americans
through churches in the intervention area, and randomized
them to either HBV education and HBV testing at enroll-
ment (the intervention group), or to a delayed intervention,
where these services could be accessed at a later stage (the
control group). A statistically significant increase in HBV
screening was observed in the early intervention group
compared with controls [39].
The Dutch study recruited first-generation Turkish res-
idents of Rotterdam to a culturally tailored Internet-based
intervention aiming to promote HBV screening [51].
Through a clustered randomized design, participants were
computer-randomized to receive either a behavioral tai-
loring intervention (BT), one combining behavioral and
cultural tailoring, or just generic online information. An
invitation letter explained the intervention and directed
recipients to the project’s website, which ‘‘streamed’’
participants into one of the three intervention groups.
Approximately 15 % of those sent letters logged onto the
website, and overall screening uptake was similar
(*45 %) across all three intervention groups [51]. This
was the first documented intervention using the Internet to
increase hepatitis B testing rates in a migrant community;
Hepatol Int (2014) 8:478–492 487
123
given the low participation rate, these findings need further
validation [51].
The remaining 25 papers describe nonrandomized
screening interventions which incorporated some form of
community outreach and education in addition to
screening.
Program components and services provided
Programs publicized hepatitis B screening using ethnic
media and flyers/posters; all but 3 (88 %) offered com-
munity education using lectures and workshops, educa-
tional brochures, articles published in ethnic newspapers,
and web-based resources. City-wide programs in San
Francisco and New York had sophisticated multimedia
campaigns and marketing strategies and developed pro-
gram-specific websites with tailored educational
information.
Vaccination (either free of charge or subsidized) was
offered by 12 programs (48 %); most US programs and the
New Zealand programs offered it. Vaccination was not
included in the Dutch, Taiwanese, and Australian pro-
grams, which may be due to the ability to access vacci-
nation through other means.
One-year follow-up was provided by the two controlled
intervention studies, with the San Francisco Hep B Free
[55] and the BFreeNYC [34] programs also providing
follow-up, constrained by limited resources. Long-term
follow-up is offered by the New Zealand [47] and Aus-
tralian programs [54].
The Dutch [49–52], Australian [54], and New Zealand
programs [46] as well as some US programs offered link-
age to care [35, 43, 56] or employed a patient navigator to
negotiate the medical system on the patients’ behalf [41,
57]. Programs in Michigan [41], Texas [43], Virginia [48],
Florida [44], and Southern California offered referrals to
insured participants [33]; 71 % of the US programs iden-
tified by Rein et al. [25] provided treatment referrals, with
29 % providing antiviral treatment.
A complete CHB care package encompassing hepati-
tis B screening, HCC surveillance, ongoing disease moni-
toring, and treatment was offered by BFreeNYC [34] and
San Francisco Hepatitis B Free [55] and programs in New
Zealand [46, 47], Australia [54], and The Netherlands [49].
Some programs provided hepatitis C testing [29, 37, 43,
45, 50, 52], contact tracing (the New Zealand program)
[45] or physician education about HBV (some US and the
Australian program) [32, 34, 54] or disease advocacy.
San Francisco seeks to become the first HBV-free city,
with the Hep B Free Campaign offering screening, vacci-
nation, and treatment to all Asian and Pacific Islander
residents (representing 30 % of its population) [10]. To
improve disease surveillance, the city established a
population-based chronic hepatitis B registry, with
enhanced disease surveillance ascertaining transmission
patterns and participants’ ability to access hepatitis care
[58]. The Australian program includes a CHB disease
registry to optimize patient follow-up and collect popula-
tion-level data on CHB disease characteristics [53, 54].
Program outcomes
Most interventions reported results in terms of the number
of people reached, number of screenings performed, and
estimated HBsAg prevalence overall and by ethnic groups.
The most comprehensive outcome measures were doc-
umented by the BFreeNYC program, which also conducted
a random survey of Asian Americans 2 years after the
program ended [34]. They documented a 34 % increase in
new CHB cases reported from areas with a high Asian
population during its 4 years of activity, with 57 % of
people with CHB remaining in care until the end of the
program [34]. BFreeNYC reached over 1 million people,
provided education for 11,000, screened approximately
9,000 people, and diagnosed and managed 6 cases of HCC
and 22 of end-stage liver failure [34].
During its first 2 years, the San Francisco Hep B Free
program reached over 200,000 people and tested 3,315
Asian–Pacific Islanders at standalone screening sites [31]
and 12,000 people through the Jade Ribbon Campaign
[32]; 6.5 % were chronically infected and referred for
follow-up care [31]. The largest ‘‘yield’’ of screening
occurred in higher education establishments with a large
proportion of Asian students, Asian street festivals and
fairs [55].
The HepBFree New Zealand program tested 177,000
people, 5.7 % being HBsAg-positive; significant regional
and ethnic differences in HBsAg-positive rates were
observed among Maori (5.6 %), Pacific islander (7.3 %),
and Asian people (6.2 %) [47]. Successful outreach raised
CHB community awareness and led to effective partner-
ships with local health care providers [47, 59].
With few exceptions, programs did not report the size of
their target population, but the Kawerau study in New
Zealand was able to test 93 % of the town population,
finding HBsAg prevalence rates of 4.2 % among European
residents and 18.2 % amongst the Maori population [28].
Rein et al. [25] reported results for five US screening
programs screening over 1,600 participants over 7 months;
95 % of those screened were foreign-born, and most
(56 %) did not have a regular medical practitioner or health
insurance (54 %).
Screening uptake was highest for programs using an
outreach and partnership model (OPM) [31, 33, 37, 59]; the
COM at community fairs yielded fewer screenings [30, 34,
45]; screening offered by clinical experts had low uptake.
488 Hepatol Int (2014) 8:478–492
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The Healthy Asian American Projects initiative in Michi-
gan targeted Chinese, Korean, and Vietnamese Asian
Americans at eight health fairs over 2 years; despite wide
advertising, education, and distribution of brochures in six
languages, screening rates remained low, attributed to
‘‘resistance by Asian Americans to participate in clinical
studies’’ [41]. Similar outcomes were documented by a
program in Florida, where free access to specialists and a
screening incentive led to 1.6 and 2.6 % of participants
taking up screening in the first and second year, respec-
tively [44].
Successful completion of hepatitis B vaccination was
monitored by the Hepatitis B initiative in Boston (59 %)
[40] and Washington (79 %) [36], as well as the Three for
Life (85 %) [37] and Jade Ribbon campaigns in San
Francisco [32].
Linkage to care (beyond vaccination) was offered by 11
programs, mostly in countries with socialized medicine: in
Europe 2 (or 66 %) out of 3 (or 66 %) and in Australia–
New Zealand 2 (or 66 %) out of 3 (or 66 %) programs
offered linkage to care, compared with the USA, where 6
(30 %) out of 20 did so. In five US screening programs,
54 % of participants had no insurance cover and/or no
regular health care provider [25]; in Michigan 45 % [41],
in San Francisco 46 % [31], and in Los Angeles 74 % [33]
of people accessing the programs were uninsured.
BFreeNYK was able to maintain 57 % of its 1,100 CHB
patients in care until the end of the 4-year program [34],
but high rates of loss to follow-up occurred in other pro-
grams: just 77 % of the 7,000 people screened by the Asian
Pacific Liver Center in Los Angeles could be traced
6 months later [33].
Program costs
Cost of care estimates were provided by the BFreeNYC
program, with annual cost per infected patient estimated at
1,598 USD [34]. Rein et al. [27] compared the costs of
four types of community screening in the USA and found
that CCM was the least costly per screened participant,
albeit screening fewer participants, while the partnership
and contract model (PCM) screened most participants, at
the highest cost per screening.
Discussion
Over the last 30 years, many initiatives have sought to
increase hepatitis B screening rates in high-risk commu-
nities, by targeting migrant populations in the USA, Aus-
tralia, and The Netherlands, as well as indigent populations
in New Zealand and Taiwan. A few programs successfully
reached large numbers of people, but the majority screened
modest numbers: the 31 programs active across the USA in
2008 screened a total of 21,817 people, or approximately
700 people per program. Even assuming seroprevalence
rates of 10 % in the target populations, this translates into
just 2,000 new CHB diagnoses. Given that the USA has
approximately 2 million infected people [60], of whom
60 % (i.e., 1.2 million) are unaware of their infection [19],
opportunistic screening cannot make a significant impact in
populations with low access to medical care [19], making
community-based screening a more attractive option.
Successful programs achieved significant buy-in from tar-
get communities, delivering culturally appropriate educa-
tional initiatives and offering comprehensive care
packages, as exemplified by the BFreeNYC [34], San
Francisco Hep B Free [55], and the New Zealand [46, 47]
and Australian programs [53, 54].
Large US programs grappled with the challenge of
offering ongoing care to uninsured participants, as two-
thirds of people not attending follow-up arrangements had
no financial means or medical insurance [33]. The BFree-
NYC program was the only US program able to provide
Box 1 Factors ensuring effective program delivery
Community awareness and education
Using community networks and grassroots work to promote
programs
Ethnic and language-specific program promotion
Maintaining an ongoing awareness campaign
Culturally and linguistically tailored outreach materials
Making effective use of ethnic media to publicize events and
resources
Screening models incorporating community outreach
Bilingual or culturally aware staff delivering intervention
Offering flexible and varied screening options at suitable times
and places
Developing and implementing standardized screening and
follow-up procedures
Useful ‘‘add-ons’’
CHB monitoring and treatment protocols integrated with medical
records
Integrating CHB screening into routine care
Health provider education, training, and support
Access to patient navigators to provide linkages and patient
assistance
Political endorsement and support
Advocacy at local and national level
On the ‘‘wish list’’
Ability to provide affordable linkage to care, including ongoing
disease monitoring and treatment
Large and renewable volunteer pool (or ideally funding for staff)
Disease register to facilitate follow-up and epidemiological data
collection
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free treatment over its 4-year existence [34]; the San
Francisco programs faced great logistical challenges to
provide access to care to uninsured [32]. Availability of
free medical care did not ensure successful referral to care:
one-third of patients eligible for treatment in a Dutch study
did not see a specialist [61], and the uptake of the Sydney-
based program was low initially, despite providing free
screening and treatment [50].
Successful programs found innovative ways to leverage
organizational and individual resources, including garner-
ing political and practical support [34, 62]. To ensure
program sustainability, costs and outcomes require close
scrutiny; while CHB screening integrated with primary
care services is less labor intensive and less costly, evi-
dence from the USA [27] and New Zealand [47] suggests it
delivers lower screening rates. Conversely, outreach mod-
els deliver greater community involvement, but at higher
costs. The New York program suggested main-streaming
these activities into primary care and educating primary
care providers [34].
Key program challenges included the high cost of
screening and limited ability to offer affordable long-term
care, so new approaches and financing arrangements are
critical to make access to care a reality for many. Most US
programs relied upon volunteer support and commitment
from communsity-based organizations, and reliance on
their continued support may be unsustainable in the long
run [34, 55]. Given that low community awareness, wide-
spread misinformation, and persisting cultural stigma
remain significant barriers, sustained community aware-
ness-raising campaigns, complemented by culturally
appropriate care delivery models, are acutely needed [24].
The noted ‘‘resistance by Asian Americans to participate
in clinical studies’’ [41] prompted recommendations for
educational interventions to be developed in native Asian
languages, rather than using translated English resources
[41]. Although previous research suggested that Asian
Americans prefer to access health information from health
care providers speaking their language [63], programs
providing access to health specialists speaking Asian lan-
guages and offering screening incentives did not achieve a
great deal of success [34].
The linkage to care and treatment is critical to ensure
program buy-in and effectiveness, and this poses serious
challenges in many countries with high CHB disease
prevalence, but with costs of antiviral therapies likely to
fall in the future, a community-based model of CHB
diagnosis could still provide the impetus for offering a
large-scale treatment program for a larger population.
Box 1 provides some summary points of critical success
factors and program limitations and challenges.
Conclusions
This review suggests that community-based hepatitis B
screening is an active area of research and experimentation
in countries with large migrant populations, such as the
USA, The Netherlands, New Zealand, and Australia. Suc-
cessful programs used a range of strategies to increase
community awareness and knowledge and leveraged
community partnerships to achieve significant community
engagement and penetration. They combined HBV edu-
cation, community empowerment, and collaborative part-
nerships, and they incorporated the target population’s
values in program design and implementation. In addition
to screening and vaccination, ‘‘ideal’’ programs must offer
access to ongoing care and support, inclusive of antiviral
therapy and HCC screening.
Many unanswered questions still remain regarding
optimal funding mechanisms, program sustainability, the
best way of ensuring linkage to care, and how to develop,
select, and implement the most effective strategies of
screening, disease surveillance, and community engage-
ment and education.
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